BCM
MBIO icon

BlueCrest Capital Management’s Mustang Bio MBIO Stock Holding History

BlueCrest Capital Management’s Portfolio MBIO Stock Details MBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-24
Closed -$196K – 1686
2018
Q1 		$196K Buy
+24
New +$204K 0.01% 1285

Other funds holding MBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlueCrest Capital Management's MBIO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Mustang Bio (MBIO) in Q2 2018, closing a stake of 24 shares — an estimated $196K sold.

BlueCrest Capital Management first reported a position in MBIO in Q1 2018 and held it in 1 quarter. The position peaked at $196K in Q1 2018. 36 funds tracked by Wall St. Rank hold MBIO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Mustang Bio position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 24 Mustang Bio shares in Q2 2018, an estimated $196K.
  • BlueCrest Capital Management first reported a position in Mustang Bio in Q1 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Mustang Bio position peaked at $196K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held Mustang Bio as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.